Swog Cancer Research Network

This study tested whether adding the drug everolimus to standard hormone therapy for one year could help prevent breast cancer from returning in people with high-risk, hormone receptor-positive, HER2-negative breast cancer. About 1,900 participants were randomly assigned to recei…

This phase 3 study tests whether adding daratumumab to the standard drug lenalidomide as maintenance therapy after a stem cell transplant can help people with multiple myeloma live longer and keep the cancer from coming back. About 1,100 participants will receive either lenalidom…

This study tests a combination of the targeted drug amivantamab plus two chemotherapy drugs (carboplatin and paclitaxel) in 50 people with head and neck cancer that has come back or spread. The goal is to see if this mix can shrink tumors or slow the disease. Participants have al…

This study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab works better than standard treatments for people with advanced non-small cell lung cancer that has already been treated with other immunotherapies. N-803 activates natural killer cells…

This study tests whether adding the drug asciminib to usual treatment works better for people newly diagnosed with a specific type of leukemia (Ph+ ALL). About 55 adults will receive a combination of asciminib, dasatinib, prednisone, and blinatumomab. The main goal is to see if t…

This study tests a drug called sacituzumab govitecan in 44 people with HER2-negative breast cancer that has spread to the brain. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering chemotherapy directly to them. The goal is to see if it can shr…

This study tests two different versions of a bladder cancer treatment called BCG, which uses a harmless bacteria to boost the immune system. About 1000 people with early-stage bladder cancer that hasn't spread to muscle will receive either a standard BCG or a different strain, wi…

This study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation). The drug is designed to block the cancer's growth signal. About 116 participants will receive the treatment to see if it shrinks tumors and how safe…

This study tests whether adding ruxolitinib to standard tyrosine kinase inhibitors (TKIs) can further lower leukemia levels in people with chronic myeloid leukemia (CML) who still have detectable disease. About 81 adults with chronic-phase CML will receive either a TKI alone or a…

This study tests whether a combination of two drugs (ramucirumab and pembrolizumab) works better than standard chemotherapy for people with advanced or returning non-small cell lung cancer who have already tried immunotherapy. About 838 participants will be randomly assigned to o…

This study tests whether a special nutrition drink, given before and after bladder removal surgery, can boost the immune system and reduce problems like infections. About 200 adults with bladder cancer are taking part. The goal is to see if better nutrition leads to fewer complic…

This study tests a drug called selpercatinib (LOXO-292) in people with a specific type of advanced or recurrent non-small cell lung cancer that has a RET gene fusion. The drug works by blocking enzymes that help cancer cells grow. About 124 participants will receive the treatment…

This study tests whether taking two drugs (eflornithine and sulindac) together can prevent new high-risk growths or a second colon cancer in people who have already been treated for stage 0 to III colon or rectal cancer. About 354 participants will take the drug combination or a …

This study tests whether regularly checking in on symptoms, along with providing educational materials, helps young women (ages 18-44) with early-stage hormone-positive breast cancer continue taking their hormone therapy as prescribed. Many women stop these pills early due to sid…

This study looks at whether online decision-support tools help women with atypical hyperplasia or lobular carcinoma in situ (conditions that raise breast cancer risk) make informed choices about taking chemoprevention drugs. About 412 women and their doctors will use these tools.…

This study looks at over 1,300 cancer patients to find out who is more likely to develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track factors like age, gender, and pre-existing conditions to create a prediction tool. The g…

This study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers will collect blood samples from 956 newly diagnosed patients and track their health over time. The goal is to see if this mark…

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will be involved, and their doctors will either use the…

This study tests a program where a financial navigator helps cancer patients and their partners understand insurance, set up payment plans, and find cost-saving options. The goal is to see if this support reduces financial hardship and improves quality of life. About 331 patients…